OneMedNet (ONMD)
Market Price (11/8/2026): $5.14 | Market Cap: $29.9 MilSector: Health Care | Industry: Health Care Technology
OneMedNet (ONMD)
Market Price (11/8/2026): $5.14Market Cap: $29.9 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 217% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, AI in Healthcare Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -65%, 3Y Excs Rtn is -166% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -696% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 173% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -472%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -473% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33% High stock price volatilityVol 12M is 132% Key risksONMD key risks include [1] severe financial instability and a going concern warning, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 217% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Artificial Intelligence. Themes include Health Data Analytics, AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -65%, 3Y Excs Rtn is -166% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -10 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -696% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 173% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -472%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -473% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -33% |
| High stock price volatilityVol 12M is 132% |
| Key risksONMD key risks include [1] severe financial instability and a going concern warning, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 11/6/2026
OneMedNet (ONMD) stock has lost about 30% since 7/31/2026 because of the following key factors:
1. OneMedNet executed a 1-for-10 reverse stock split in late September 2026, a corporate action often perceived negatively by the market. This move was undertaken to address Nasdaq's minimum bid price listing requirements. Despite a series of positive commercial announcements during this period, selling pressure on the stock continued following the reverse split, contributing to the stock's decline.
2. The company continues to face persistent net losses and significant liquidity concerns, leading to "substantial doubt about its ability to continue as a going concern." For fiscal Q2 2026, which ended on June 30, 2026, OneMedNet reported a net loss of $2.2 million. This ongoing financial instability, combined with limited liquidity, remains a core concern for investors. The company's fiscal year ends on December 31.
Show more
OneMedNet (ONMD) stock has lost about 30% since 7/31/2026 because of the following key factors:
1. OneMedNet executed a 1-for-10 reverse stock split in late September 2026, a corporate action often perceived negatively by the market. This move was undertaken to address Nasdaq's minimum bid price listing requirements. Despite a series of positive commercial announcements during this period, selling pressure on the stock continued following the reverse split, contributing to the stock's decline.
2. The company continues to face persistent net losses and significant liquidity concerns, leading to "substantial doubt about its ability to continue as a going concern." For fiscal Q2 2026, which ended on June 30, 2026, OneMedNet reported a net loss of $2.2 million. This ongoing financial instability, combined with limited liquidity, remains a core concern for investors. The company's fiscal year ends on December 31.
Show more
Updated on 11/6/2026
OneMedNet (ONMD) stock has lost about 30% since 7/31/2026 because of the following key factors:
1. OneMedNet executed a 1-for-10 reverse stock split in late September 2026, a corporate action often perceived negatively by the market. This move was undertaken to address Nasdaq's minimum bid price listing requirements. Despite a series of positive commercial announcements during this period, selling pressure on the stock continued following the reverse split, contributing to the stock's decline.
2. The company continues to face persistent net losses and significant liquidity concerns, leading to "substantial doubt about its ability to continue as a going concern." For fiscal Q2 2026, which ended on June 30, 2026, OneMedNet reported a net loss of $2.2 million. This ongoing financial instability, combined with limited liquidity, remains a core concern for investors. The company's fiscal year ends on December 31.
3. OneMedNet has experienced substantial share dilution, with its outstanding shares increasing approximately 15-fold over the past four fiscal years. The number of shares outstanding grew from roughly 3.46 million in fiscal year 2021 to 54.43 million by fiscal year 2025. This continuous issuance of new shares to fund operations has placed downward pressure on the stock price.
4. The stock's status as a thinly traded micro-cap company with limited analyst coverage exacerbates price volatility and investor uncertainty. OneMedNet is characterized by ongoing net losses and minimal institutional analyst attention, with only one reported "Sell" rating and no credible published price targets. These factors contribute to amplified price swings and a lack of clear market consensus, further impacting the stock's performance.
Show less
OneMedNet (ONMD) stock has lost about 30% since 7/31/2026 because of the following key factors:
1. OneMedNet executed a 1-for-10 reverse stock split in late September 2026, a corporate action often perceived negatively by the market. This move was undertaken to address Nasdaq's minimum bid price listing requirements. Despite a series of positive commercial announcements during this period, selling pressure on the stock continued following the reverse split, contributing to the stock's decline.
2. The company continues to face persistent net losses and significant liquidity concerns, leading to "substantial doubt about its ability to continue as a going concern." For fiscal Q2 2026, which ended on June 30, 2026, OneMedNet reported a net loss of $2.2 million. This ongoing financial instability, combined with limited liquidity, remains a core concern for investors. The company's fiscal year ends on December 31.
3. OneMedNet has experienced substantial share dilution, with its outstanding shares increasing approximately 15-fold over the past four fiscal years. The number of shares outstanding grew from roughly 3.46 million in fiscal year 2021 to 54.43 million by fiscal year 2025. This continuous issuance of new shares to fund operations has placed downward pressure on the stock price.
4. The stock's status as a thinly traded micro-cap company with limited analyst coverage exacerbates price volatility and investor uncertainty. OneMedNet is characterized by ongoing net losses and minimal institutional analyst attention, with only one reported "Sell" rating and no credible published price targets. These factors contribute to amplified price swings and a lack of clear market consensus, further impacting the stock's performance.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -28.6% change in ONMD stock from 7/31/2026 to 11/7/2026 was primarily driven by a -32.2% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 11072026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.20 | 5.14 | -28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 10.4% |
| P/S Multiple | 30.2 | 20.5 | -32.2% |
| Shares Outstanding (Mil) | 6 | 6 | -4.7% |
| Cumulative Contribution | -28.6% |
Market Drivers
7/31/2026 to 11/7/2026| Return | Correlation | |
|---|---|---|
| ONMD | -28.6% | |
| Market (SPY) | -1.6% | 6.2% |
| Sector (XLV) | 13.7% | 5.6% |
Fundamental Drivers
The -52.4% change in ONMD stock from 4/30/2026 to 11/7/2026 was primarily driven by a -52.6% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 11072026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.80 | 5.14 | -52.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 7.1% |
| P/S Multiple | 43.2 | 20.5 | -52.6% |
| Shares Outstanding (Mil) | 5 | 6 | -6.2% |
| Cumulative Contribution | -52.4% |
Market Drivers
4/30/2026 to 11/7/2026| Return | Correlation | |
|---|---|---|
| ONMD | -52.4% | |
| Market (SPY) | 2.6% | 12.5% |
| Sector (XLV) | 27.1% | 1.3% |
Fundamental Drivers
The -75.8% change in ONMD stock from 10/31/2025 to 11/7/2026 was primarily driven by a -87.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 11072026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.20 | 5.14 | -75.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 216.5% |
| P/S Multiple | 169.8 | 20.5 | -87.9% |
| Shares Outstanding (Mil) | 4 | 6 | -36.5% |
| Cumulative Contribution | -75.8% |
Market Drivers
10/31/2025 to 11/7/2026| Return | Correlation | |
|---|---|---|
| ONMD | -75.8% | |
| Market (SPY) | 8.7% | 8.9% |
| Sector (XLV) | 29.8% | 1.7% |
Fundamental Drivers
The -90.7% change in ONMD stock from 10/31/2023 to 11/7/2026 was primarily driven by a -93.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312023 | 11072026 | Change |
|---|---|---|---|
| Stock Price ($) | 55.10 | 5.14 | -90.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 1 | 0.0% |
| P/S Multiple | � | 20.5 | 0.0% |
| Shares Outstanding (Mil) | 0 | 6 | -93.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2023 to 11/7/2026| Return | Correlation | |
|---|---|---|
| ONMD | -90.7% | |
| Market (SPY) | 81.9% | 3.6% |
| Sector (XLV) | 55.4% | -2.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ONMD Return | 2% | 3% | -92% | 68% | -19% | -53% | -95% |
| Peers Return | -2% | -48% | 4% | -26% | -19% | -1% | -68% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| ONMD Win Rate | 86% | 83% | 67% | 50% | 42% | 36% | |
| Peers Win Rate | 47% | 35% | 48% | 40% | 42% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| ONMD Max Drawdown | - | -1% | -93% | -78% | -77% | -68% | |
| Peers Max Drawdown | -29% | -58% | -44% | -44% | -48% | -53% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IQV, VEEV, HCAT, DH, CERT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/6/2026 (YTD)
How Low Can It Go
| Event | ONMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -65.9% | -18.8% |
| % Gain to Breakeven | 193.5% | 23.1% |
| Time to Breakeven | 62 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -25.1% | -7.8% |
| % Gain to Breakeven | 33.6% | 8.5% |
| Time to Breakeven | 4 days | 18 days |
In The Past
OneMedNet's stock fell -65.9% during the 2025 US Tariff Shock. Such a loss loss requires a 193.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ONMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -65.9% | -18.8% |
| % Gain to Breakeven | 193.5% | 23.1% |
| Time to Breakeven | 62 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -25.1% | -7.8% |
| % Gain to Breakeven | 33.6% | 8.5% |
| Time to Breakeven | 4 days | 18 days |
In The Past
OneMedNet's stock fell -65.9% during the 2025 US Tariff Shock. Such a loss loss requires a 193.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About OneMedNet (ONMD)
OneMedNet (ONMD), as described, operates as a Special Purpose Acquisition Company (SPAC). Its primary business objective is to effect a business combination with one or more existing operating businesses. This process involves various transaction types, including mergers, capital stock exchanges, asset acquisitions, stock purchases, or reorganizations, through which the SPAC essentially acts as a shell to bring a private company to the public market.
As a SPAC, the company does not offer traditional products or services in the manner of an operating business. Instead, its core "service" is to identify and complete an acquisition. OneMedNet specifically intends to focus its acquisition efforts on target businesses within the data centers and internet technology sectors, which represent its primary market for potential business combinations.
AI Analysis | Feedback
- A public venture capital firm for data centers and internet technology.
- A blank check company searching for a data center or internet technology business.
- A publicly traded acquisition fund specifically targeting tech infrastructure.
AI Analysis | Feedback
- Business Combinations: Effecting mergers, capital stock exchanges, asset acquisitions, stock purchases, or reorganizations with one or more businesses.
AI Analysis | Feedback
OneMedNet (symbol: ONMD) operates a healthcare data platform that provides de-identified medical imaging and related clinical data for research and development purposes. It primarily sells its services to other companies. While specific individual customer names are not widely disclosed by OneMedNet, its major customer categories include:
- Pharmaceutical and Biotechnology Companies: These companies utilize OneMedNet's Real World Data (RWD) for drug discovery, clinical trial design, post-market surveillance, and generating real-world evidence to support regulatory submissions and market access strategies.
- Medical Device Companies: Manufacturers of medical devices leverage the data for product development, performance monitoring, validation, and demonstrating the effectiveness and safety of their devices.
- Artificial Intelligence (AI) and Machine Learning (ML) Developers: Companies specializing in AI and ML use OneMedNet's extensive datasets of medical images and associated clinical data to train, validate, and enhance their diagnostic and therapeutic algorithms and solutions.
- Academic and Clinical Research Institutions: Universities and research organizations access the de-identified data for various scientific studies, advancing medical knowledge and understanding of diseases.
AI Analysis | Feedback
Microsoft Corporation (Symbol: MSFT)
Alphabet Inc. (Symbols: GOOGL, GOOG)
AI Analysis | Feedback
Aaron Green - President and Chief Executive Officer
Aaron Green assumed the role of President and CEO of OneMedNet on March 29, 2024, after serving as President since May 2023. He possesses over two decades of experience in healthcare IT, with a notable history of driving growth and business transformations. Prior to joining OneMedNet, Green held positions such as Vice President Cloud Solutions at Optum Insights, General Manager Radiology Imaging at Change Healthcare (NASDAQ: CHNG), and Division Vice President, Sales at McKesson (NYSE: MCK).
Robert Golden - Chief Financial Officer and Corporate Secretary
Robert Golden was appointed as Chief Financial Officer of OneMedNet, effective September 10, 2024, and his position was made permanent as of January 31, 2025. He brings over 40 years of financial management experience, including roles as Managing Partner of Cohen, Bender & Golden LLP since 2015, and CFO of Promo Shop, Inc. since 2008 and iKahan Media, Inc. since 2014. His expertise spans operational efficiency, cash flow optimization, financial planning, and mergers and acquisitions.
Dr. Jeffrey Yu - Chief Medical Officer and Vice President
Dr. Jeffrey Yu is the founder of OneMedNet, establishing the company in 2009. He also serves as the Chairman of the Board. Dr. Yu is a board-certified Radiologist with additional fellowship training and board certification in Nuclear Medicine, and he has dedicated 28 years of sophisticated healthcare IT experience to the company.
Steven Chartier - VP Engineering Chief of Data
Carrie Manthei - VP, Clinical Data Curation
Aaron Green assumed the role of President and CEO of OneMedNet on March 29, 2024, after serving as President since May 2023. He possesses over two decades of experience in healthcare IT, with a notable history of driving growth and business transformations. Prior to joining OneMedNet, Green held positions such as Vice President Cloud Solutions at Optum Insights, General Manager Radiology Imaging at Change Healthcare (NASDAQ: CHNG), and Division Vice President, Sales at McKesson (NYSE: MCK).
Robert Golden - Chief Financial Officer and Corporate Secretary
Robert Golden was appointed as Chief Financial Officer of OneMedNet, effective September 10, 2024, and his position was made permanent as of January 31, 2025. He brings over 40 years of financial management experience, including roles as Managing Partner of Cohen, Bender & Golden LLP since 2015, and CFO of Promo Shop, Inc. since 2008 and iKahan Media, Inc. since 2014. His expertise spans operational efficiency, cash flow optimization, financial planning, and mergers and acquisitions.
Dr. Jeffrey Yu - Chief Medical Officer and Vice President
Dr. Jeffrey Yu is the founder of OneMedNet, establishing the company in 2009. He also serves as the Chairman of the Board. Dr. Yu is a board-certified Radiologist with additional fellowship training and board certification in Nuclear Medicine, and he has dedicated 28 years of sophisticated healthcare IT experience to the company.
Steven Chartier - VP Engineering Chief of Data
Carrie Manthei - VP, Clinical Data Curation
AI Analysis | Feedback
The key risks to OneMedNet's business, trading under the symbol ONMD, are primarily centered around its financial viability, compliance with listing standards, and the complex regulatory landscape of healthcare data.
- Poor Financial Health and Going Concern Risk: OneMedNet has a history of significant operating losses and negative net income since its inception. The company's financial strength is rated as poor, with high debt levels and negative equity, indicating that its liabilities currently exceed its assets. This has led to substantial doubt about its ability to continue as a going concern, exacerbated by low cash reserves and substantial current liabilities. Furthermore, OneMedNet has experienced negative revenue growth and significantly negative gross and operating margins.
- NASDAQ Listing Compliance and Stock Volatility: As a micro-cap stock, OneMedNet faces the ongoing challenge of maintaining compliance with NASDAQ's listing requirements, particularly concerning the minimum bid price and market value of listed securities. The company's stock is characterized by significant price fluctuations and high volatility due to low trading volume. Continued non-compliance could lead to delisting, further impacting investor confidence and access to capital.
- Regulatory Hurdles in Data Privacy: Operating in the healthcare data sector, OneMedNet is highly susceptible to changes and strict adherence to data privacy laws such as HIPAA and GDPR. Any changes in these regulations or failures in maintaining rigorous privacy standards for its imaging Real-World Data (iRWD™) platform could significantly impact its data sharing models and overall business operations.
AI Analysis | Feedback
null
AI Analysis | Feedback
OneMedNet (NASDAQ: ONMD) operates within several addressable markets related to healthcare data and medical imaging.
Real-World Data (RWD) and Real-World Evidence (RWE) Solutions
OneMedNet's flagship product, the iRWD™ platform, focuses on collecting, de-identifying, and curating regulatory-grade clinical imaging data and associated electronic health records for life sciences companies, AI developers, and pharmaceutical firms.
The addressable market for Real-World Evidence (RWE) solutions is estimated to be $60 billion (global).
Medical Image Exchange Systems
OneMedNet also offers solutions for medical image exchange.
The global medical image exchange systems market is valued at approximately US$ 4.4 billion in 2025 and is projected to reach US$ 7.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.4%. North America currently dominates this market, contributing approximately 32.3% of the global share.
Healthcare Data Annotation
Through a strategic partnership with Medcase, OneMedNet has expanded into the healthcare data annotation market.
This global market for healthcare data annotation was valued at $1.5 billion in 2025 and is projected to grow to $2.8 billion by 2030.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for OneMedNet (ONMD) over the next 2-3 years:
- Shift to Recurring Subscription Model: OneMedNet is strategically transitioning its business model from project-based work to recurring subscription partnerships. This shift is anticipated to drive predictable growth and increased annual recurring revenue (ARR). The company reported record bookings of $2.79 million in 2025, marking a 4.1-fold increase compared to 2024, largely due to larger enterprise deals and this move towards recurring subscriptions.
- Expansion of Healthcare Provider Network and iRWD™ Platform: The continuous expansion of OneMedNet's iRWD™ platform and its integrated network of healthcare sites is a key growth driver. The company has integrated over 2,130 healthcare sites into its platform and reported a 37% year-over-year increase in its network in 2025, encompassing 186 million clinical exams. This expanding network enhances the volume and diversity of data available, attracting more customers in the life sciences and AI sectors.
- Strategic Partnerships and Advanced Data Integration (e.g., Palantir Foundry): Collaborations and technological integrations are expected to accelerate revenue growth. The commercial launch of OneMedNet's Real-World Data (RWD) platform, powered by Palantir Foundry, is a significant driver. This integration enhances AI-driven search capabilities and scalable data feeds, leading to higher average recurring revenue and larger deal sizes. Additionally, partnerships such as those with ViuHealth to enhance autoimmune datasets and Risorius for neuro data are expected to boost recurring revenue from life sciences and AI customers.
- Growing Demand for Real-World Data and AI in Healthcare: The increasing demand for Real-World Data (RWD) and artificial intelligence (AI) solutions within the healthcare and life sciences industries presents a significant growth opportunity for OneMedNet. The company's platform is designed to provide de-identified medical imaging and electronic health records, fueling innovation for drugmakers, medical device pioneers, and AI developers. There is a notable industry-wide shift towards AI-driven precision in medical imaging and a rising demand in sectors like cardiac AI diagnostics, which OneMedNet is positioned to address.
AI Analysis | Feedback
Share Issuance
- In November 2023, OneMedNet completed a business combination with Data Knights Acquisition Corp., which included approximately $200 million or more in rollover equity to OneMedNet equity holders.
- The company completed a private placement in July 2024, generating approximately $4.6 million in gross proceeds from the sale of common stock and pre-funded warrants.
- In June 2025, OneMedNet raised approximately $3.7 million in gross proceeds through private placement transactions with accredited investors, including some of its founders and directors.
Inbound Investments
- The business combination with Data Knights Acquisition Corp. in November 2023 implied a pro-forma enterprise value of approximately $317 million.
- In March 2024, OneMedNet secured up to $4.54 million in funding from an institutional investor through a private placement of senior convertible notes, intended for working capital, growth acceleration, network enhancement, and AI-driven solution development.
- Off the Chain Capital has made strategic investments in OneMedNet, recognizing the company's platform and market position.
Outbound Investments
- In July 2024, OneMedNet utilized $1.8 million of the net proceeds from a private placement to acquire Bitcoin ($BTC).
- In September 2024, a portion of the net proceeds from a subsequent private placement was planned for purchasing Bitcoin ($BTC).
Capital Expenditures
- OneMedNet's capital expenditures were -$43,000 in the last 12 months (as of March 2026).
- Adjusted Capital Expenditures for OneMedNet Corporation were -$3.0 thousand in 2025.
- The company is undertaking ongoing investments for long-term growth, focusing on new real-world data offerings, network expansion, and strategic partnerships like the integration of Palantir's AI Platform.
Peer Outperformance in Health Care Technology
ONMD has trailed 80% of its 20 Health Care Technology peers over 5Y. Health Care Technology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Health Care Technology constituents that ONMD has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
19%
of 32 industry peers · -65.3% return
3Y
13%
of 24 industry peers · -90.3% return
5Y
20%
of 20 industry peers · -94.9% return
No Health Care Technology peer with a comparable growth profile has beaten ONMD by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Technology is ONMD's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 6.4% | 54.7% | 91.6% | CAH 507% · MCK 390% · COR 176% |
| Health Care Services | 20 | 32.4% | 24.2% | 7.1% | HIMS 212% · RDNT 120% · DGX 100% |
| Managed Health Care | 8 | 55.2% | -1.0% | -2.4% | OSCR 80% · HQY 52% · ELV 8% |
| Health Care Facilities | 26 | 16.4% | 19.8% | -6.8% | THC 276% · NHC 212% · EHC 179% |
| Health Care Equipment | 50 | 4.0% | 12.4% | -18.2% | UFPT 361% · GKOS 294% · TMDX 180% |
| Pharmaceuticals | 61 | -8.8% | 11.8% | -37.3% | LQDA 975% · XERS 679% · KNSA 537% |
| Health Care Supplies | 11 | 23.1% | 16.0% | -41.2% | LNTH 248% · HAE 61% · MMSI 26% |
| Life Sciences Tools & Services | 108 | -6.4% | -14.3% | -74.5% | AXGN 264% · MEDP 189% · NTRA 168% |
| Biotechnology | 365 | -23.8% | -33.1% | -81.5% | ELVN 1194% · TRVI 1125% · DNTH 995% |
| Health Care Technology ← | 21 | -21.7% | -51.6% | -82.9% | VEEV -5% · DOCS -52% |
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is OneMedNet Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.59 |
| Mkt Cap | 1.0 |
| Rev LTM | 355 |
| Op Inc LTM | -1 |
| FCF LTM | 38 |
| FCF 3Y Avg | 48 |
| CFO LTM | 59 |
| CFO 3Y Avg | 67 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.7% |
| Rev Chg 3Y Avg | 6.4% |
| Rev Chg Q | 6.2% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | -1.2% |
| Op Inc Chg 3Y Avg | 10.5% |
| Op Mgn LTM | -3.8% |
| Op Mgn 3Y Avg | -3.2% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 16.1% |
| CFO/Rev 3Y Avg | 18.7% |
| FCF/Rev LTM | 11.2% |
| FCF/Rev 3Y Avg | 13.9% |
Price Behavior
Price Behavior
| Market Price | $5.14 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/24/2021 | |
| Distance from 52W High | -73.6% | |
| 50 Days | 200 Days | |
| DMA Price | $5.41 | $7.09 |
| DMA Trend | down | down |
| Distance from DMA | -5.0% | -27.5% |
| 3M | 1YR | |
| Volatility | 114.8% | 131.6% |
| Downside Capture | 116.49 | 191.26 |
| Upside Capture | 33.09 | 28.28 |
| Correlation (S&P 500) | 8.7% | 10.0% |
ONMD Betas & Captures as of 10/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -2.73 | -1.77 | -0.97 | 0.60 | 0.66 | 0.50 |
| Up Beta | -9.80 | 0.32 | 0.32 | 1.86 | 1.85 | -0.43 |
| Down Beta | -3.55 | -0.98 | -0.59 | 0.70 | -0.18 | 0.16 |
| Up Capture | -422% | -269% | -181% | -50% | -25% | 20% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 7 | 15 | 25 | 50 | 109 | 311 |
| Down Capture | 28% | -53% | 61% | 145% | 140% | 111% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 15 | 28 | 39 | 74 | 138 | 426 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ONMD | |
|---|---|---|---|---|
| ONMD | -70.8% | 131.6% | -0.33 | - |
| Sector ETF (XLV) | 28.6% | 16.9% | 1.31 | 1.8% |
| Equity (SPY) | 9.5% | 13.6% | 0.40 | 9.2% |
| Gold (GLD) | 1.6% | 28.7% | 0.05 | -1.6% |
| Commodities (DBC) | 38.4% | 21.2% | 1.42 | -4.6% |
| Real Estate (VNQ) | 11.3% | 14.2% | 0.51 | -6.6% |
| Bitcoin (BTCUSD) | -27.2% | 43.6% | -0.61 | 2.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ONMD | |
|---|---|---|---|---|
| ONMD | -44.9% | 186.9% | 0.30 | - |
| Sector ETF (XLV) | 8.3% | 15.4% | 0.35 | -1.6% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 2.8% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | -1.1% |
| Commodities (DBC) | 8.1% | 19.6% | 0.30 | -2.1% |
| Real Estate (VNQ) | 1.3% | 18.9% | -0.04 | -3.3% |
| Bitcoin (BTCUSD) | 4.0% | 51.6% | 0.26 | -0.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ONMD | |
|---|---|---|---|---|
| ONMD | -25.6% | 180.6% | 0.29 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.59 | -1.6% |
| Equity (SPY) | 15.0% | 18.0% | 0.70 | 2.7% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | -1.1% |
| Commodities (DBC) | 7.5% | 18.1% | 0.33 | -2.0% |
| Real Estate (VNQ) | 5.9% | 20.7% | 0.24 | -3.3% |
| Bitcoin (BTCUSD) | 60.0% | 66.3% | 1.00 | -0.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/6/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/23/2024 | 56.5% | 64.6% | -37.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 56.5% | 64.6% | |
| Median Negative | -37.7% | ||
| Max Positive | 56.5% | 64.6% | |
| Max Negative | -37.7% | ||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/23/2024 | 56.5% | 64.6% | -37.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 0 | 0 | 1 |
| Median Positive | 56.5% | 64.6% | |
| Median Negative | -37.7% | ||
| Max Positive | 56.5% | 64.6% | |
| Max Negative | -37.7% | ||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 12/17/2024 | 10-Q |
| 06/30/2024 | 12/11/2024 | 10-Q |
| 03/31/2024 | 12/05/2024 | 10-Q |
| 12/31/2023 | 04/09/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 10/02/2023 | 424B3 |
| 09/30/2022 | 12/18/2023 | 10-Q/A |
| 12/31/2021 | 07/22/2022 | S-4 |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 12/17/2024 | 10-Q |
| 06/30/2024 | 12/11/2024 | 10-Q |
| 03/31/2024 | 12/05/2024 | 10-Q |
| 12/31/2023 | 04/09/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 10/02/2023 | 424B3 |
| 09/30/2022 | 12/18/2023 | 10-Q/A |
| 12/31/2021 | 07/22/2022 | S-4 |
Insider Activity
Updated 10/13/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 10132026 | 5.54 | 45,126 | 249,998 | 4,968,494 | Form |
| 2 | Kosasa, Thomas | Direct | Buy | 10132026 | 5.78 | 129,758 | 750,001 | 11,465,052 | Form | |
| 3 | Green, Aaron | Chief Executive Officer | Direct | Sell | 10092026 | 6.48 | 1,667 | 10,802 | 1,606,852 | Form |
| 4 | Green, Aaron | Chief Executive Officer | Direct | Sell | 10092026 | 7.39 | 5,000 | 36,960 | 1,845,324 | Form |
| 5 | Golden, Robert Lawrence | Chief Financial Officer | Direct | Sell | 10092026 | 6.63 | 3,000 | 19,890 | 605,259 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 10132026 | 5.54 | 45,126 | 249,998 | 4,968,494 | Form |
| 2 | Kosasa, Thomas | Direct | Buy | 10132026 | 5.78 | 129,758 | 750,001 | 11,465,052 | Form | |
| 3 | Green, Aaron | Chief Executive Officer | Direct | Sell | 10092026 | 6.48 | 1,667 | 10,802 | 1,606,852 | Form |
| 4 | Green, Aaron | Chief Executive Officer | Direct | Sell | 10092026 | 7.39 | 5,000 | 36,960 | 1,845,324 | Form |
| 5 | Golden, Robert Lawrence | Chief Financial Officer | Direct | Sell | 10092026 | 6.63 | 3,000 | 19,890 | 605,259 | Form |
| 6 | Golden, Robert Lawrence | Chief Financial Officer | Direct | Sell | 10092026 | 6.30 | 3,000 | 18,900 | 594,033 | Form |
| 7 | Golden, Robert Lawrence | Chief Financial Officer | Direct | Sell | 10092026 | 6.60 | 2,500 | 16,500 | 642,121 | Form |
| 8 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 9142026 | 0.63 | 142,857 | 90,000 | 5,621,658 | Form |
| 9 | Kosasa, Thomas | Direct | Buy | 8072026 | 0.69 | 1,449,275 | 1,000,000 | 12,791,323 | Form | |
| 10 | Green, Aaron | Chief Executive Officer | Direct | Buy | 6232026 | 0.57 | 36,650 | 21,011 | 1,087,192 | Form |
| 11 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 6232026 | 0.63 | 158,730 | 100,000 | 5,531,658 | Form |
| 12 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 6172026 | 0.58 | 172,414 | 100,000 | 5,000,574 | Form |
| 13 | Green, Aaron | Chief Executive Officer | Direct | Buy | 6152026 | 0.54 | 18,702 | 10,092 | 1,003,508 | Form |
| 14 | Green, Aaron | Chief Executive Officer | Direct | Buy | 6152026 | 0.56 | 36,920 | 20,605 | 1,027,475 | Form |
| 15 | Kosasa, Thomas | Direct | Buy | 6142026 | 0.63 | 158,730 | 100,000 | 10,765,991 | Form | |
| 16 | Kosasa, Thomas | Direct | Buy | 5202026 | 0.93 | 268,817 | 250,000 | 15,745,034 | Form | |
| 17 | Kosasa, Thomas | Direct | Buy | 4242026 | 0.89 | 280,898 | 249,999 | 14,828,581 | Form | |
| 18 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 4242026 | 0.83 | 903,614 | 750,000 | 6,830,765 | Form |
| 19 | Kosasa, Thomas | Direct | Buy | 4242026 | 0.84 | 595,238 | 500,000 | 13,759,560 | Form | |
| 20 | Green, Aaron | Chief Executive Officer | Direct | Sell | 12232025 | 1.20 | 61,555 | 73,903 | 2,166,006 | Form |
| 21 | Green, Aaron | Chief Executive Officer | Direct | Sell | 12232025 | 2.23 | 64,767 | 144,722 | 4,168,813 | Form |
| 22 | Casaburi, Eric | Direct | Buy | 11262025 | 3.05 | 10,000 | 30,500 | 199,699 | Form | |
| 23 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.03 | 1,250 | 1,288 | 7,293,660 | Form |
| 24 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.02 | 17,200 | 17,544 | 7,221,572 | Form |
| 25 | Kosasa, Thomas | Direct | Buy | 11262025 | 0.93 | 6,000 | 5,599 | 14,687,172 | Form | |
| 26 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.93 | 5,700 | 5,301 | 6,568,379 | Form |
| 27 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.95 | 400 | 380 | 6,704,219 | Form |
| 28 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.89 | 1,250 | 1,112 | 6,280,439 | Form |
| 29 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.91 | 700 | 637 | 6,420,435 | Form |
| 30 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.86 | 2,100 | 1,806 | 6,067,062 | Form |
| 31 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.87 | 11,810 | 10,275 | 6,135,782 | Form |
| 32 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.81 | 11,670 | 9,453 | 5,703,059 | Form |
| 33 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.85 | 24,319 | 20,671 | 5,974,772 | Form |
| 34 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.82 | 10,890 | 8,930 | 5,743,956 | Form |
| 35 | Kosasa, Thomas | Direct | Buy | 11262025 | 0.86 | 581,395 | 500,000 | 13,531,404 | Form | |
| 36 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.80 | 17,000 | 13,600 | 5,595,147 | Form |
| 37 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.69 | 21,374 | 14,748 | 4,814,084 | Form |
| 38 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.69 | 173,350 | 119,611 | 4,799,336 | Form |
| 39 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.75 | 13,300 | 9,975 | 5,086,658 | Form |
| 40 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.77 | 15,000 | 11,550 | 5,212,061 | Form |
| 41 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.77 | 16,500 | 12,705 | 5,200,511 | Form |
| 42 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.42 | 1,666,666 | 700,000 | 2,829,712 | Form |
| 43 | Kosasa, Thomas | Direct | Buy | 11262025 | 0.42 | 1,190,476 | 500,000 | 6,364,174 | Form | |
| 44 | Kosasa, Thomas | Direct | Buy | 11262025 | 0.38 | 55,000 | 21,016 | 3,240,523 | Form | |
| 45 | Kosasa, Thomas | Direct | Buy | 11262025 | 0.49 | 47,000 | 22,861 | 4,098,321 | Form | |
| 46 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.99 | 100 | 99 | 2,735,563 | Form |
| 47 | Casaburi, Eric | Direct | Buy | 11262025 | 0.87 | 1,300 | 1,131 | 48,263 | Form | |
| 48 | Casaburi, Eric | Direct | Buy | 11262025 | 0.85 | 500 | 425 | 46,049 | Form | |
| 49 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.66 | 1,600 | 1,056 | 1,671,335 | Form |
| 50 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.68 | 800 | 544 | 1,720,894 | Form |
| 51 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.22 | 100 | 122 | 3,086,510 | Form |
| 52 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.41 | 14 | 20 | 3,567,055 | Form |
| 53 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.34 | 10 | 13 | 3,389,948 | Form |
| 54 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.35 | 13 | 18 | 3,415,233 | Form |
| 55 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.19 | 2,237 | 2,662 | 3,010,449 | Form |
| 56 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.10 | 913 | 1,004 | 2,780,307 | Form |
| 57 | Casaburi, Eric | Direct | Buy | 11262025 | 0.92 | 4,100 | 3,772 | 49,381 | Form | |
| 58 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.52 | 1,203 | 626 | 1,313,852 | Form |
| 59 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.69 | 105 | 72 | 1,742,551 | Form |
| 60 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.68 | 106 | 72 | 1,717,225 | Form |
| 61 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.65 | 214 | 139 | 1,641,396 | Form |
| 62 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.60 | 350 | 210 | 1,515,007 | Form |
| 63 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.62 | 100 | 62 | 1,565,290 | Form |
| 64 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.65 | 100 | 65 | 1,640,965 | Form |
| 65 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.79 | 100 | 79 | 1,994,324 | Form |
| 66 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.84 | 16 | 13 | 2,120,463 | Form |
| 67 | Casaburi, Eric | Direct | Buy | 11262025 | 0.74 | 2,000 | 1,480 | 36,686 | Form | |
| 68 | Casaburi, Eric | Direct | Buy | 11262025 | 0.72 | 575 | 414 | 34,254 | Form | |
| 69 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.82 | 100 | 82 | 2,069,963 | Form |
| 70 | Casaburi, Eric | Direct | Buy | 11262025 | 0.77 | 2,000 | 1,540 | 36,190 | Form | |
| 71 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.19 | 2 | 2 | 3,003,852 | Form |
| 72 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.45 | 1,357 | 1,968 | 3,660,152 | Form |
| 73 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.14 | 400 | 456 | 2,876,090 | Form |
| 74 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.04 | 950 | 988 | 2,623,385 | Form |
| 75 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.56 | 5,386 | 3,016 | 1,412,060 | Form |
| 76 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.55 | 2,304 | 1,267 | 1,383,882 | Form |
| 77 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.55 | 740 | 407 | 1,382,615 | Form |
| 78 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.52 | 720 | 374 | 1,306,815 | Form |
| 79 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.49 | 5,035 | 2,467 | 1,231,069 | Form |
| 80 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.48 | 60 | 29 | 1,181,928 | Form |
| 81 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.61 | 362 | 221 | 1,501,998 | Form |
| 82 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.75 | 15 | 11 | 1,846,447 | Form |
| 83 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.81 | 20 | 16 | 1,994,150 | Form |
| 84 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.85 | 20 | 17 | 2,092,610 | Form |
| 85 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.86 | 100 | 86 | 2,117,212 | Form |
| 86 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.83 | 10 | 8 | 2,043,272 | Form |
| 87 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.84 | 180 | 151 | 2,067,882 | Form |
| 88 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.82 | 20 | 16 | 2,018,499 | Form |
| 89 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.03 | 10 | 10 | 2,535,411 | Form |
| 90 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 0.92 | 10 | 9 | 2,264,630 | Form |
| 91 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.09 | 50 | 55 | 2,683,083 | Form |
| 92 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.06 | 3,040 | 3,222 | 2,609,184 | Form |
| 93 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.36 | 30 | 41 | 3,343,497 | Form |
| 94 | Yu, Jeffrey | Chief Medical Officer | Direct | Buy | 11262025 | 1.31 | 3,300 | 4,323 | 3,220,535 | Form |
| 95 | Golden, Robert Lawrence | Chief Financial Officer | Direct | Buy | 11262025 | 1.71 | 300 | 513 | 513 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 11/7/2026